Compare NVTS & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NVTS | MESO |
|---|---|---|
| Founded | 2014 | 2004 |
| Country | United States | Australia |
| Employees | N/A | 81 |
| Industry | Semiconductors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.1B |
| IPO Year | 2020 | N/A |
| Metric | NVTS | MESO |
|---|---|---|
| Price | $14.82 | $15.24 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | ★ $6.68 | N/A |
| AVG Volume (30 Days) | ★ 28.8M | 203.3K |
| Earning Date | 05-05-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $45,916,000.00 | N/A |
| Revenue This Year | N/A | $629.74 |
| Revenue Next Year | $71.28 | $30.65 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.80 | $9.88 |
| 52 Week High | $19.79 | $21.50 |
| Indicator | NVTS | MESO |
|---|---|---|
| Relative Strength Index (RSI) | 59.25 | 48.19 |
| Support Level | $7.05 | $14.44 |
| Resistance Level | $17.79 | $16.49 |
| Average True Range (ATR) | 1.60 | 0.43 |
| MACD | 0.58 | 0.01 |
| Stochastic Oscillator | 54.31 | 39.08 |
Navitas Semiconductor Corp develops ultra-efficient gallium nitride (GaN) semiconductors that are revolutionizing power electronics. GaN power ICs integrate GaN power with drive, control, and protection to enable fast charging, high power density, and energy savings for mobile, consumer, enterprise, eMobility, and new energy markets. The company operates as one reportable segment, the design, development, manufacture, and marketing of integrated circuits and related components. Geographically, the company operates in Hong Kong, China, Europe, the United States, Rest of Asia, and Others. The majority of revenue is generated from Hong Kong.
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.